

## PHARMACY POLICY STATEMENT

### North Carolina Marketplace

<b>DRUG NAME</b>	<b>Austedo (deutetrabenazine)</b>
BENEFIT TYPE	Pharmacy
STATUS	Prior Authorization Required

Austedo, approved by the FDA in 2017, is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated

## Tardive Dyskinesia (TD)

For initial authorization:

1.

## References:

1. Austedo [package insert]. North Wales, PA; Teva Pharmaceuticals, Inc. 2023.
2. Huntington Study group. Effect of deutetrabenazine on chorea among patients with huntington disease: a randomized clinical trial. *JAMA*. 2016; 316(1):40-50. doi: 10.1001/jama.2016.8655.
3. Claassen DO, Carroll B, De Boer LM, et al. Indirect tolerability comparison of deutetrabenazine and tetrabenazine for huntington disease. *J Clin Mov Dis* 2017(4):3. doi: 10.1186/s40734-017-0051-5.
4. Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Psychiatry*. 2017;4(8):595-604. doi:10.1016/S2215-0366(17)30236-5
5. Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. *Neurology*. 2017;88(21):2003-2010. doi:10.1212/WNL.0000000000003960
6. Fernandez HH, Stamler D, Davis MD, et al. Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. *J Neurol Neurosurg Psychiatry*. 2019;90(12):1317-1323. doi:10.1136/jnnp-2018-319918
7. Hauser RA, Barkay H, Fernandez HH, et al. Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-